PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
- Conditions
- Complicated Urinary Tract Infection
- Interventions
- Drug: NXL104/ceftazidimeDrug: Imipenem/Cilastatin
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 137
- Registration Number
- NCT00690378
- Locations
- 🇺🇸
Four Rivers Clinical Research Inc, Paducah, Kentucky, United States
🇺🇸Summa Health System Hospitals, Akron, Ohio, United States
🇺🇸Remington-Davis, Columbus, Ohio, United States
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: PF-04136309Drug: Placebo
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 159
- Registration Number
- NCT00689273
- Locations
- 🇺🇸
Arthritis & Rheumatic Care Center, South Miami, Florida, United States
🇺🇸Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States
🇰🇷Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
- Conditions
- Invasive Candidiasis
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 216
- Registration Number
- NCT00689338
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2013-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 318
- Registration Number
- NCT00687193
- Locations
- 🇯🇵
Pfizer Investigational Site, Saitama, Japan
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2012-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 186
- Registration Number
- NCT00684645
- Locations
- 🇨🇿
Pfizer Investigational Site, Zlin, Czech Republic
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: desvenlafaxine succinate (DVS) SRDrug: Placebo
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2186
- Registration Number
- NCT00683800
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
- Conditions
- Complicated Skin and Skin Structure InfectionsComplicated Intra-abdominal Infections
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2011-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 621
- Registration Number
- NCT00683332
- Locations
- 🇵🇭
Pfizer Investigational Site, Manila, Philippines
Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 450
- Registration Number
- NCT00683137
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
Study of Different Doses of a Novel Treatment for Onychomycosis
- Conditions
- Distal, Subungual Onychomycosis
- Interventions
- Drug: AN2690, 2.5%Drug: AN2690, 5%Drug: AN2690, 7.5%Drug: Vehicle
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00679770
- Locations
- 🇺🇸
Academic Dermatology Associates, Albuquerque, New Mexico, United States
🇺🇸DermResearch, Inc., Austin, Texas, United States
🇺🇸Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC, San Antonio, Texas, United States
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
- Conditions
- Onychomycosis
- Interventions
- Drug: AN2690 Solution, 5.0%Drug: AN2690 Solution, 7.5%
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00679523
- Locations
- 🇲🇽
MIRC / OCA Hospital, Monterrey, Mexico
🇲🇽Instituto Dermatologico Jalisciense, Guadalajara, Mexico
🇲🇽IMIC, Mexico City, Mexico